文献速递白血病

维奈克拉联合低剂量阿糖胞苷靶向治疗急性髓系白血病分子可测量残留病及低原始细胞复发:一项前瞻性II期研究(VALDAC)

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
PubMed 文献 · J Clin Oncol · 2024-03-01

这项前瞻性II期研究评估维奈克拉联合低剂量阿糖胞苷治疗首次可测量残留病(MRD)或低原始细胞复发的急性髓系白血病的安全性和疗效。共纳入48例成人患者,MRD复发组26例,低原始细胞复发组22例。MRD复发组中46%达到MRD阴性缓解,低原始细胞复发组中73%达到完全缓解(CR/CRh/CRi)。结论认为该方案耐受性好且高效。

要点

  • 维奈克拉600mg每日一次D1-28联合低剂量阿糖胞苷每日一次D1-10,28天为一周期。
  • MRD复发组第2周期时69%观察到MRD下降1个log10,46%达到MRD阴性缓解。
  • 低原始细胞复发组73%达到CR/CRh/CRi,两队列中位总生存均未达到。

核心结论

  • 对于首次缓解后出现MRD或低原始细胞复发的急性髓系白血病,维奈克拉联合低剂量阿糖胞苷耐受性好且高度有效。

研究设计与样本

  • 前瞻性II期研究,纳入48例成人急性髓系白血病患者,其中MRD复发26例,低原始细胞复发(原始细胞5%-15%)22例。
  • 治疗方案为维奈克拉600mg每日一次D1-28联合低剂量阿糖胞苷每日一次D1-10,28天为一周期。
  • 主要目标为MRD复发队列的MRD缓解或低原始细胞复发队列的完全缓解(CR/CRh/CRi)。

主要发现

  • 中位年龄67岁(范围18-80),94%曾接受强化化疗,中位治疗4个周期,17%完成≥12个周期。
  • 低原始细胞复发组较MRD复发组有更多≥3级贫血(32% vs 4%;P=0.02)和感染(36% vs 8%;P=0.03),而4级中性粒细胞减少(32% vs 23%)或血小板减少(27% vs 15%)与MRD复发组相当。
  • 分子MRD复发标志包括突变NPM1(77%)、CBFB::MYH11(4%)、RUNX1::RUNX1T1(4%)或KMT2A::MLLT3(4%),另有3例(12%)为IDH1/2 log10升高。
  • MRD复发组第2周期时69%观察到MRD下降1个log10,46%达到MRD阴性缓解;低原始细胞复发组73%达到CR/CRh/CRi。
  • 共21例(44%)接受造血细胞移植,两队列中位总生存均未达到,估计2年总生存率MRD复发组为67%(95%CI 50-89),低原始细胞复发组为53%(95%CI 34-84)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS: Patients with either MRD (≥1 log10 rise) or oligoblastic relapse (blasts 5%-15%) received venetoclax 600 mg once daily D1-28 plus LDAC once daily D1-10 in 28-day cycles. The primary objective was MRD response in the MRD relapse cohort or complete remission (CR/CRh/CRi) in the oligoblastic relapse cohort. RESULTS: Forty-eight adults with either MRD (n = 26) or oligoblastic (n = 22) relapse were enrolled. Median age was 67 years (range, 18-80) and 94% had received previous intensive chemotherapy. Patients received a median of four cycles of therapy; 17% completed ≥12 cycles. Patients with oligoblastic relapse had more grade ≥3 anemia (32% v 4%; P = .02) and infections (36% v 8%; P = .03), whereas grade 4 neutropenia (32 v 23%) or thrombocytopenia (27 v 15%) were comparable with the MRD relapse cohort. Markers of molecular MRD relapse included mutant NPM1 (77%), CBFB::MYH11 (4%), RUNX1::RUNX1T1 (4%), or KMT2A::MLLT3 (4%). Three patients with a log10 rise in IDH1/2 (12%) were included. By cycle 2 in the MRD relapse cohort, a log10 reduction in MRD was observed in 69%; 46% achieved MRD negative remission. In the oligoblastic relapse cohort, 73% achieved CR/CRh/CRi. Overall, 21 (44%) underwent hematopoietic cell transplantation. Median overall survival (OS) was not reached in either cohort. Estimated 2-year OS rate was 67% (95% CI, 50 to 89) in the MRD and 53% (95% CI, 34 to 84) in the oligoblastic relapse cohorts. CONCLUSION: For AML in first remission and either MRD or oligoblastic relapse, venetoclax plus LDAC is well tolerated and highly effective.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tiong IS, Hiwase DK, Abro E, et al. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). J Clin Oncol. 2024. PMID: 38427924. doi:10.1200/JCO.23.01599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。